|
Matinas BioPharma Holdings, Inc. (MTNB): Marketing Mix [Jan-2025 Updated] |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
Matinas BioPharma Holdings, Inc. (MTNB) Bundle
In the dynamic world of biotechnology, Matinas BioPharma Holdings, Inc. (MTNB) emerges as a pioneering force, leveraging its innovative NANOsystem technology to revolutionize treatments for rare metabolic and inflammatory diseases. With a strategic focus on precision medicine and groundbreaking drug candidates like MAT9001, this New Jersey-based pharmaceutical innovator is positioning itself at the forefront of transformative healthcare solutions. Dive into the comprehensive marketing mix that reveals how MTNB is reshaping the pharmaceutical landscape, one breakthrough at a time.
Matinas BioPharma Holdings, Inc. (MTNB) - Marketing Mix: Product
Therapeutic Development Focus
Matinas BioPharma specializes in developing novel therapeutics for rare and serious metabolic and inflammatory diseases using its proprietary lipid-based drug delivery platform technology.
NANOsystem Drug Delivery Platform
| Platform Technology | Key Characteristics |
|---|---|
| NANOsystem | Lipid-based drug delivery technology designed to enhance drug performance and bioavailability |
Primary Drug Candidate: MAT9001
MAT9001 is the company's lead product candidate targeting cardiovascular lipid disorders.
- Developed for treatment of severe lipid disorders
- Potential alternative to existing lipid management therapies
- Utilizes NANOsystem delivery technology
COVID-19 and Acute Lung Injury Research
| Research Area | Product Status |
|---|---|
| Acute Lung Injury Treatment | Ongoing development of potential therapeutic interventions |
| COVID-19 Complications | Exploring potential treatment strategies |
Precision Medicine Approach
Matinas BioPharma emphasizes innovative pharmaceutical solutions with a focus on precision medicine strategies.
- Targeted therapeutic development
- Advanced drug delivery mechanisms
- Personalized treatment potential
Product Portfolio Highlights
| Product | Therapeutic Area | Development Stage |
|---|---|---|
| MAT9001 | Cardiovascular Lipid Disorders | Clinical Development |
| COVID-19 Therapeutic | Respiratory Complications | Research Phase |
Matinas BioPharma Holdings, Inc. (MTNB) - Marketing Mix: Place
Headquarters Location
Bedminster, New Jersey, United States
Geographic Distribution Channels
| Region | Distribution Focus | Market Penetration |
|---|---|---|
| North America | Primary Healthcare Systems | 85% of Clinical Operations |
| Global Pharmaceutical Markets | Research and Development | Emerging International Partnerships |
Clinical Trial Locations
- Multiple Research Centers in United States
- Academic Medical Institutions
- Specialized Pharmaceutical Research Facilities
Strategic Partnership Distribution Network
| Partner Type | Collaboration Focus |
|---|---|
| Pharmaceutical Research Institutions | Drug Development |
| Medical Research Centers | Clinical Trial Management |
Market Access Strategy
Primary Distribution Channels:
- Direct Pharmaceutical Research Engagement
- Collaborative Clinical Development Platforms
- Specialized Biopharmaceutical Networks
Matinas BioPharma Holdings, Inc. (MTNB) - Marketing Mix: Promotion
Investor Presentations and Scientific Conferences
Matinas BioPharma actively participates in key industry events to showcase its pipeline and research advancements. In 2023, the company presented at:
| Conference | Date | Presentation Focus |
|---|---|---|
| H.C. Wainwright Global Investment Conference | September 2023 | MAT9001 clinical development |
| Oppenheimer Healthcare Conference | November 2023 | Corporate strategy update |
Press Releases and Earnings Communication
Communication frequency and key metrics:
- Quarterly earnings reports filed consistently
- Average of 12-15 press releases annually
- Investor relations website updates every 30-45 days
Digital Platform Engagement
| Platform | Follower Count | Engagement Rate |
|---|---|---|
| 3,200 followers | 2.4% | |
| 1,800 followers | 1.9% |
Industry Conference Participation
2023-2024 Conference Presentations:
- Biotechnology Innovation Organization (BIO) International Convention
- JP Morgan Healthcare Conference
- Needham Healthcare Conference
Clinical Trial Communication Strategy
Key Communication Channels:
- ClinicalTrials.gov updates
- Investor relations press releases
- Scientific journal publications
Matinas BioPharma Holdings, Inc. (MTNB) - Marketing Mix: Price
Stock Price and Market Performance
As of January 2024, Matinas BioPharma Holdings, Inc. (MTNB) trades on NASDAQ with the following financial characteristics:
| Metric | Value |
|---|---|
| Current Stock Price | $0.15 per share |
| 52-Week Low | $0.10 |
| 52-Week High | $0.28 |
| Market Capitalization | $48.3 million |
Pricing Strategy Considerations
The company's pricing strategy is influenced by several key factors:
- Research and development investment
- Clinical trial progression
- Potential therapeutic product valuation
- Investor perception of future drug development
Fundraising and Capital Structure
Matinas BioPharma's financial approach includes:
| Funding Method | Details |
|---|---|
| Equity Offerings | Raised $12.5 million in 2023 |
| Outstanding Shares | 322 million shares |
| Cash and Equivalents | $22.6 million (as of Q3 2023) |
Valuation Metrics
Key financial indicators impacting company valuation:
- MAT9001 clinical trial progress
- Potential cardiovascular drug approval
- Research and development expenditure
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.